Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160003/S024

PRO-Kinetic Energy Coronary Stent System

Biotronik AG · Decision date Jun 5, 2026

FDA DECISIONP160003/S024

What did the FDA approve?

FDA records P160003/S024 as a supplement to PMA P160003, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jun 5, 2026.

FDA approval order statement

the introduction of a new production site for supply of the hypotube and a new hypotube extrusion process
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Jun 5, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160003/S024
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
MAF
Decision code
APPR
Decision date
Jun 5, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, CORONARY.

Applicant
Biotronik AG
Product code
MAF
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160003/S024 received

    Application receipt date recorded by FDA.

  2. P160003/S026 · Related supplement

    PRO-Kinetic Energy Coronary Stent System

  3. P160003/S022 · Related supplement

    PRO-Kinetic Energy Coronary Stent System

  4. P160003/S024 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P160003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160003

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA supplementApr 1, 2026FDA
Biotronik AGPMA supplementApr 15, 2026FDA

Explore the linked device profile

Other records with product code MAF

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMar 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records